A putative class action targeting Rodan + Fields, LLC in California federal court could draw fresh attention to the use of prostaglandin analogs in cosmetic eyelash enhancers, an issue that has sparked FDA enforcement action in the past, as well as unfair competition suits from Latisse owner Allergan plc.
Filed April 13 in California’s Northern District, Oakland Division, the suit is based on the premise that “disclosing the true risks and side effects of Lash Boost on the product...
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on HBW Insight for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?